Search
News & Events
Smartphone donationsThe Diabetes Research Team is requesting donations of old iPhones for a new study investigating the effect of real time CGM on every day diabetes management.
News & Events
Diabete$ Re$earch in Au$traliaIt may surprise you to know that the Australian government has invested almost $300 million dollars since 2000 towards research and clinical trials for diabetes
News & Events
Low Carbohydrate DietsCarbohydrate restriction is used by some individuals with type 1 diabetes to reduce glucose excursions after eating a meal.
News & Events
Recruitment for AdDIT now completeYoung people diagnosed with Type 1 Diabetes are at risk of complications from their diabetes including kidney, heart, eye and vascular disease.
News & Events
WA teenager with type 1 diabetes on a mission to become a pro-cyclistA wiry tall teenager, who was struggling somewhat with his blood glucose control, he turned up on his trusty bike, and we had something in common to talk about.
T1D can be a traumatic diagnosis for children and young people, and often involves strict adherence to painful treatments, comorbid mental health conditions, and shortened life expectancy.
Research
Stillbirth in Iceland 1996–2021: Incidence and etiologyThis study describes the stillbirth rate in Iceland 1996-2021 and the causes of stillbirth according to the Stockholm classification of stillbirth, comparing time periods and gestational age groups.
Research
LeukaemiaLeukaemia, also spelled leukemia, is a cancer that develops in the bone marrow and results in abnormal white blood cells. It is the most common cancer in children, accounting for almost a third of all childhood & teen cancers.
Research
PertussisPertussis, also known as whooping cough, is a highly contagious respiratory disease.
Research
Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in AustraliaAustralia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.